Susan Moran

CIK: 0001835225

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

CBIO

CRESCENT BIOPHARMA, INC.

Director

TYRA

Tyra Biosciences, Inc.

Director

BCAB

BioAtla, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

CBIO
CRESCENT BIOPHARMA, INC.
Jun 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
11.1K shares-
TYRA
Tyra Biosciences, Inc.
May 28, 2026
Award(A)
Stock Option (Right to Buy)
Direct
13.2K shares-
CBIO
GLYCOMIMETICS INC
Jun 23, 2025
Award(A)
Stock Option (Right to Buy)
Direct
9K shares-
BCAB
BioAtla, Inc.
Jun 18, 2025
Award(A)
Direct
23.5K shares-
TYRA
Tyra Biosciences, Inc.
May 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
22.2K shares-

		Type	Shares	Price		Ownership
Jun 2, 2026	CBIO CRESCENT BIOPHARMA, INC.	Award(A) Stock Option (Right to Buy)	11,050	-	-	Direct
May 28, 2026	TYRA Tyra Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	13,160	-	-	Direct
Jun 23, 2025	CBIO GLYCOMIMETICS INC	Award(A) Stock Option (Right to Buy)	9,023	-	-	Direct
Jun 18, 2025	BCAB BioAtla, Inc.	Award(A)	23,500	-	-	Direct
May 29, 2025	TYRA Tyra Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	22,200	-	-	Direct

1-5 of 5 transactions

About Moran Susan

Moran Susan (SEC CIK 0001835225) files insider reports with the SEC as Director of CRESCENT BIOPHARMA, INC. (CBIO), Director of Tyra Biosciences, Inc. (TYRA) and Director of BioAtla, Inc. (BCAB).

Signal8 holds 6 ownership filings by Moran Susan (1 Form 3, 5 Form 4), filed between Jun 2, 2025 and Jun 3, 2026. Those filings report 5 transactions, from May 29, 2025 to Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Moran Susan's filings is in CARLSBAD, CA.

Recent filings by Moran Susan

Jun 2, 2026: Grant or award of CBIO derivative securities (Form 4, code A).
May 28, 2026: Grant or award of TYRA derivative securities (Form 4, code A).
Jun 23, 2025: Grant or award of CBIO derivative securities (Form 4, code A).
Jun 18, 2025: Grant or award of BCAB shares (Form 4, code A).
May 29, 2025: Grant or award of TYRA derivative securities (Form 4, code A).

Other insiders filing for CRESCENT BIOPHARMA, INC. (CBIO)

Lynch Ryan
Pinkas Jan, Chief Scientific Officer
Im Ellie Eunkyung, Chief Medical Officer
Scalzo Richard William, Chief Financial Officer
Bispham Barbara Harlin
Brumm Joshua T, Chief Executive Officer

How to read Form 4 transaction codes